854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models

• Elizabeth Gray,
• Shyra Gardai,
• Kelly Hensley,
• Sean Allred,
• Esther Trueblood,
• John Gosink,
• Katie Snead,
• Michelle Ulrich,
• Alyson Smith,
• Angela Epp,
• Disha Sahetya,
• Julie Hahn,
• Jane Haass,
• Sasha Lucas,
• Rogely Boyce,
• Piper Treuting,
• Chris Frantz,
• Jason Schrum,
• Natalya Nazarenko

Affiliations

Elizabeth Gray

1 Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, UK

Shyra Gardai

Seattle Genetics, Inc., Bothell, WA, USA

Kelly Hensley

1Seattle Genetics, Inc., Bothell, USA

Sean Allred

1Seattle Genetics, Inc., Bothell, USA

Esther Trueblood

1Seattle Genetics, Inc., Bothell, USA

John Gosink

1Seattle Genetics, Inc., Bothell, USA

Katie Snead

1Seattle Genetics, Inc., Bothell, WA, USA

Michelle Ulrich

Seattle Genetics, Inc., Bothell, WA, USA

Alyson Smith

1Seagen, Inc., Bothell, WA, USA

Angela Epp

1Seagen, Inc., Bothell, WA, USA

Disha Sahetya

1Seagen, Inc., Bothell, WA, USA

Julie Hahn

1Seagen, Inc., Bothell, WA, USA

Jane Haass

1Seagen, Inc., Bothell, WA, USA

Sasha Lucas

1Seagen, Inc., Bothell, WA, USA

Rogely Boyce

2Beechy Ridge ToxPath LLC, Clay, WV, USA

Piper Treuting

1Seagen, Inc., Bothell, WA, USA

Chris Frantz

1Seagen, Inc., Bothell, WA, USA

Jason Schrum

1Seagen, Inc., Bothell, WA, USA

Natalya Nazarenko

1Seagen, Inc., Bothell, WA, USA